To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:6571
Name non-invasive bladder urothelial carcinoma
Definition
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma bladder urothelial carcinoma non-invasive bladder urothelial carcinoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00794950 Phase II Sunitinib Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma Completed USA 0
NCT03317158 Phase Ib/II Durvalumab BCG solution + Durvalumab ADAPT-BLADDER: Modern Immunotherpy in BCG-Relapsing Urothelial Carcinoma of the Bladder Recruiting USA 0
NCT03672240 Phase Ib/II APL-1202 APL-1202 + BCG solution Study of APL-1202 in Non-Muscle Invasive Bladder Cancer Patients Who Are Resistant to One Induction Course of BCG Treatment (NMIBC) Completed USA 0
NCT04106115 Phase Ib/II Durvalumab + S-588210 DURvalumab in Combination With S-488210/S-488211 vAccine in Non-muscle Invasive Bladder CancEr (DURANCE) Recruiting GBR 0
NCT04149574 Phase III BCG solution + Nivolumab BCG solution A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) Terminated USA | SWE | NLD | ITA | ISR | GRC | FRA | ESP | DEU | CAN | BRA | AUT | AUS | ARG 3
NCT04172675 Phase II Erdafitinib Gemcitabine Mitomycin C A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Active, not recruiting USA | POL | ITA | GBR | FRA | ESP | DEU | CZE | BRA | BEL | AUS | ARG 5
NCT04640623 Phase II Cetrelimab + TAR-200 TAR-200 A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy Active, not recruiting USA | NLD | ITA | GRC | GBR | FRA | ESP | DEU | CAN | BEL | AUS 5
NCT04752722 Phase Ib/II EG-70 EG-70 in NMIBC Patients Who Are BCG-Unresponsive and High-Risk NMIBC Patients Who Have Been Incompletely Treated With BCG or Are BCG-Naïve (LEGEND STUDY) Recruiting USA | FRA | ESP | DEU | CAN | AUS 1
NCT04819399 Phase I Catumaxomab Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC Unknown status DEU 0
NCT05259397 Phase I PF-06801591 + PF-07225570 PF-07225570 PF-07225570 Alone or in Combination With an Anti-PD-1 Antibody in Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Withdrawn USA | POL 0
NCT05327647 Phase II Bicalutamide A Phase II Trial of Bicalutamide in Patients Receiving Intravesical BCG for Non-muscle Invasive Bladder Cancer (BicaBCa) Recruiting CAN 0
NCT05375903 Phase I Imiquimod + Zalifrelimab Zalifrelimab A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC) Active, not recruiting USA | ITA | ESP 0
NCT05483868 Phase I AU-011 A Phase 1, Open-label Trial of AU-011 (Belzupacap Sarotalocan) in NMIBC Recruiting USA 0
NCT05521698 Phase I Apalutamide Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer Not yet recruiting USA 0
NCT05533697 Phase Ib/II mRNA-4359 + Pembrolizumab mRNA-4359 Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors Recruiting USA | GBR | ESP | AUS 0
NCT05710848 Phase Ib/II STM-416 A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer Recruiting USA 0
NCT05714202 Phase III BCG solution Cetrelimab + TAR-200 TAR-200 A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (SunRISe-3) Active, not recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | CZE | CAN | BRA | BEL | AUS | ARG 7
NCT05843448 Phase I IO102-IO103 + Pembrolizumab IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination With Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer Recruiting USA 0
NCT06111235 Phase III CG0070 A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT Recruiting USA | CAN 0
NCT06181266 Phase I ZH9 A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer (PARADIGM-1) Recruiting USA 0
NCT06253845 Phase I CG0070 Study of CG0070 After Transurethral Resection in Patients With IR NMIBC Recruiting USA 0
NCT06351904 Phase I RAG-01 A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guerin (BCG) Therapy Recruiting AUS 0
NCT06390111 Expanded access Nadofaragene firadenovec A Trial to Evaluate Efficacy of Reinduction With Nadofaragene Firadenovec in Subjects With CIS ± High-grade Ta/T1 and no Complete Response to First Nadofaragene Firadenovec Dose. (ABLE-42) Withdrawn USA 0
NCT06510374 Phase III Nadofaragene firadenovec Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer (ABLE-32) Recruiting USA | CAN 0
NCT06545955 Phase II Nadofaragene firadenovec Docetaxel + Gemcitabine + Nadofaragene firadenovec Nadofaragene firadenovec + Pembrolizumab A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (ABLE-22) Recruiting USA 0
NCT06637423 Phase Ib/II SKB264 A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) (TroFuse-027) Recruiting USA | ESP | CAN 0
NCT06770582 Phase II Fluorouracil + Mitomycin C Gemcitabine Pembrolizumab Cisplatin Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, the PARRC Trial Recruiting USA 0
NCT06833073 Phase II mRNA-4157 BCG solution + mRNA-4157 BCG solution A Clinical Study of V940 and BCG in People With Bladder Cancer (V940-011/INTerpath-011) Recruiting USA | ITA | AUS 0